| 1 |
NCT02890212 |
Recruiting |
Selenium as Augmentation Treatment for Sertraline Resistant Major Depression |
|
- Dietary Supplement: selenium supplementation
- Dietary Supplement: placebo
|
Interventional
|
Not Applicable |
- University of Sao Paulo General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depressive Rating Scale
- Montgomery-Asberg Depression Rating Scale
- Clinical Global Impression Scale
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02890212 |
Selen-2015 |
|
August 2005 |
December 2018 |
December 2018 |
September 7, 2016 |
May 4, 2018 |
|
- Instituto de Psiquiatria - Hcfmusp
São Paulo, Brazil
|
|
| 2 |
NCT02209142 |
Unknown † |
Blood Biomarkers in Major Depression |
- Major Depressive Disorder
|
- Other: blood prelevement
- Other: psychometric data collection
|
Interventional
|
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- describe a transcriptional signature of the Major Depressive Episode.
- evaluate the role played by confounding factors as genetic polymorphisms,
|
275 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02209142 |
2010-19 |
|
February 2012 |
November 2015 |
October 2016 |
August 5, 2014 |
July 27, 2016 |
|
- Assistance Publique Hopitaux de Marseille
Marseille, France
|
|
| 3 |
NCT00613912 |
Completed |
Advanced MRI in Major Depression |
- Depressive Disorder, Major
|
- Other: Magnetic Resonance Imaging
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Differences in morphological and functional cerebral MRI findings in patients suffering from major depression
|
49 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT00613912 |
AUFF-2005-740-004 |
|
March 2008 |
December 2009 |
June 2011 |
February 13, 2008 |
November 21, 2011 |
|
- Aalborg Hospital / Aarhus University Hospital
Aalborg, Jutland, Denmark
|
|
| 4 |
NCT03060967 |
Not yet recruiting |
Assessment of Hedonic and Motivational States in Major Depression ( MOODDIS) |
|
- Behavioral: Computer-based tasks
|
Interventional
|
Not Applicable |
- Institut National de la Santé Et de la Recherche Médicale, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Screening
|
- Point of subjective equality (PSE)
- Percentage of subjective discrimination (PSD)
|
72 |
All |
18 Years to 60 Years (Adult) |
NCT03060967 |
C15-88 |
MOODDIS |
June 2017 |
September 2020 |
September 2020 |
February 23, 2017 |
May 12, 2017 |
|
|
|
| 5 |
NCT01768052 |
Unknown † |
Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression |
|
- Device: functional Near Infrared Spectroscopy
|
Observational
|
|
- Mclean Hospital
- National Alliance for Research on Schizophrenia and Depression
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Change in the connectivity strength in the CCN as assessed by fMRI
- Change in brain activation in DLPFC as assessed by fNIRS monitoring
|
40 |
All |
21 Years to 45 Years (Adult) |
NCT01768052 |
2012P002394 |
|
June 2013 |
January 2016 |
January 2016 |
January 15, 2013 |
May 4, 2015 |
|
- McLean Hospital
Belmont, Massachusetts, United States - McLean Imaging Center/McLean TMS Service
Belmont, Massachusetts, United States
|
|
| 6 |
NCT03670823 |
Not yet recruiting |
Prediction of SSRI Treatment in Major Depression. |
|
- Device: SIEMENS PRISMA MRI
|
Observational
|
|
- ElMindA Ltd
- Sheba Medical Center
- Hebrew University of Jerusalem
|
Industry / Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- EEG responses to cognitive tasks in combination with the Eye-tracker Device.
- Resting state connectivity analysis
- Examine correlations between the different methods
- (and 4 more...)
|
100 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03670823 |
5323-18-SMC |
|
October 1, 2018 |
October 1, 2020 |
October 1, 2020 |
September 14, 2018 |
September 14, 2018 |
|
|
|
| 7 |
NCT03595020 |
Active, not recruiting |
Probing Prefrontal Cortex Hemodynamic Alterations for Major Depression Disorder |
- Depressive Disorder, Major
|
|
Observational
|
|
- Xijing Hospital
- Health Science Center of Xi’an Jiaotong University
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Hamilton Depression Scale-17(HAMD-17) score alterations
- facial emotion recognition
- Pittsburgh Sleep Quality Index（PSQI）
|
200 |
All |
18 Years to 35 Years (Adult) |
NCT03595020 |
KY20172012-1 |
MDD |
February 16, 2017 |
August 31, 2018 |
December 31, 2018 |
July 23, 2018 |
July 23, 2018 |
|
- Department of psychiatry, Xijing Hospital; Research Institute of Biomedical Engineering, Xi'an Jiaotong University
Xi'an, Shaanxi, China
|
|
| 8 |
NCT00286546 |
Completed |
Testosterone and Major Depression |
|
|
Observational
|
|
- University Health Network, Toronto
|
Other |
- Observational Model: Defined Population
- Observational Model: Natural History
- Time Perspective: Cross-Sectional
- Time Perspective: Prospective
|
|
100 |
Male |
40 Years to 65 Years (Adult, Older Adult) |
NCT00286546 |
002 |
|
January 2001 |
|
August 2005 |
February 3, 2006 |
September 11, 2006 |
|
- Toronto Western Hospital
Toronto, Ontario, Canada
|
|
| 9 |
NCT00445237 |
Completed |
Evaluation of Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression |
|
- Device: H1 and H2 deep TMS coils
|
Interventional
|
Phase 1 |
- Shalvata Mental Health Center
- Brainsway
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00445237 |
SH-505 |
|
May 2006 |
|
March 2008 |
March 8, 2007 |
February 5, 2009 |
|
- Shalvata MHC
Hod Hasharon, Israel
|
|
| 10 |
NCT01391221 |
Unknown † |
Inflammatory Markers and Cognitive Function in Major Depression |
|
|
Interventional
|
Phase 4 |
- Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine
- Eli Lilly and Company
- Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Cognitive function measured by CANTAB
- pain inhibition
- Allostatic load
|
20 |
All |
20 Years to 50 Years (Adult) |
NCT01391221 |
2011005 |
|
July 2011 |
August 2013 |
August 2013 |
July 11, 2011 |
July 19, 2012 |
|
- Centre de Recherche Fernand Seguin
Montreal, Quebec, Canada - Hôpital Maisonneuve Rosemont
Montreal, Quebec, Canada
|
|
| 11 |
NCT03556124 |
Recruiting |
Transcranial Direct Current Stimulation in Major Depression |
- Major Depressive Disorder
|
- Device: Active - HD tDCS
- Device: Sham - HD tDCS
- Device: Active - Conventional tDCS
- Device: Sham - Conventional tDCS
|
Interventional
|
Not Applicable |
- University of California, Los Angeles
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in non-invasive MRI measures of cerebral blood flow between baseline and end of treatment
- Change in non-invasive MRI measures of current flow
|
60 |
All |
18 Years to 55 Years (Adult) |
NCT03556124 |
17-000779
R61MH110526 |
|
February 2, 2018 |
July 31, 2022 |
July 31, 2022 |
June 14, 2018 |
June 14, 2018 |
|
- University of California, Los Angeles (UCLA)
Los Angeles, California, United States
|
|
| 12 |
NCT00208702 |
Completed |
Thyroid Medication and Antidepressants for Treating Major Depression |
|
- Drug: Triiodothyronine
- Other: Placebo
- Drug: Sertraline
|
Interventional
|
Phase 4 |
- Emory University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
153 |
All |
18 Years to 60 Years (Adult) |
NCT00208702 |
0431-1996
R01MH056946
431-1996
DSIR AT-SO |
|
September 1996 |
July 2003 |
July 2003 |
September 21, 2005 |
November 17, 2015 |
|
- Emory University
Atlanta, Georgia, United States
|
|
| 13 |
NCT00368303 |
Completed |
A Local Register Study For Major Depression Of Paroxetine Controlled Release |
- Depressive Disorder, Major
- Major Depressive Disorder (MDD)
|
- Drug: Paroxetine CR
- Drug: Paroxetine IR
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Scores on depression rating scale at treatment week 1,2,3,4,6 and 8.
- Scores on clinical impression severity and improvement items at treatment week 1, 2,3,4,6,8
|
362 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00368303 |
PCR103124 |
|
December 2006 |
|
|
August 24, 2006 |
June 4, 2012 |
|
- GSK Investigational Site
Guangzhou, Guangdong, China - GSK Investigational Site
Baoding, Hebei, China - GSK Investigational Site
Changsha, Hunan, China - (and 8 more...)
|
|
| 14 |
NCT01182103 |
Completed
Has Results |
Epigenetic Regulation of BDNF in Major Depression |
- Major Depressive Disorder
|
|
Observational
|
|
- Chang Gung Memorial Hospital
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls
- Histone Modification of MDD Patients Before and After Treatment and With Healthy Controls
- BDNF Levels of MDD Patients Before and After Treatment and Healthy Controls
|
110 |
All |
18 Years to 60 Years (Adult) |
NCT01182103 |
NSC99-2628-B-182-002-MY2 |
|
August 2010 |
July 2012 |
May 2013 |
August 16, 2010 |
August 15, 2014 |
August 15, 2014 |
- Department of Psychiatry, Chang Gung Memorial Hospital
Kaohsiung, Taiwan
|
|
| 15 |
NCT03230682 |
Recruiting |
Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder |
- Major Depressive Disorder
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Early improvement
- Response
|
80 |
All |
16 Years to 55 Years (Child, Adult) |
NCT03230682 |
KY2017-01 |
|
July 25, 2017 |
June 11, 2018 |
July 11, 2018 |
July 26, 2017 |
July 26, 2017 |
|
- Dept. of Neurology, Huashan Hospital, Fudan University
Shanghai, Shanghai, China
|
|
| 16 |
NCT00675896 |
Completed |
A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome |
|
- Drug: Quetiapine Fumarate Sustained Release
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Dr Alexander McIntyre Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- last observation carried forward (LOCF) mean change from baseline to week 8 on the Hamilton Depression Scale (HAM-D) total score.
- Change from baseline to week 8 in: Brief Pain Inventory,HAM-A,CGI-S,FIQ, Sleep Scale from the Medical Outcome Study,SDS,QLES- Short Form,PHQ-15,Global Assessment Scale,Improvement (CGI-I) score from randomisation to Week 8
|
120 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00675896 |
D1443C00007 |
|
April 2007 |
June 2011 |
July 2011 |
May 12, 2008 |
July 6, 2011 |
|
- Dr. A McIntyre Inc
Penticton, British Columbia, Canada
|
|
| 17 |
NCT01625546 |
Completed |
Whole Body Hyperthermia and Major Depression (MDD) |
- Depressive Disorder, Major
|
- Device: Whole Body Hyperthermia system
|
Interventional
|
Not Applicable |
- University of Arizona
- Dr. med. h.c. Erwin Braun Foundation
- The Depressive and Bipolar Disorder Alternative Treatment Foundation
- Brain & Behavior Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- 17-item Hamilton Rating Scale for Depression (HAM-D; derived from the 31-item instrument)
- Change in QIDS (Quick Inventory of Depressive Symptoms) Score from baseline response
- Core body temperature monitoring
- (and 6 more...)
|
34 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01625546 |
12-0147-01 |
|
July 2012 |
May 2015 |
May 2015 |
June 21, 2012 |
August 10, 2015 |
|
- University of Arizona
Tucson, Arizona, United States
|
|
| 18 |
NCT00705185 |
Completed |
Exploring a Potential Blood Test to Diagnose Major Depressive Disorder |
- Major Depressive Disorder
|
|
Observational
|
|
- Massachusetts General Hospital
- Precision Human Biolaboratories
- Cambridge Health Alliance
- (and 3 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- 16 Biological Markers; Group comparison between adults with Major Depressive Disorder and healthy controls
|
120 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00705185 |
2007-P-002525 |
Bio-TestMDD |
April 2008 |
June 2010 |
June 2010 |
June 25, 2008 |
June 8, 2010 |
|
- University of Connecticut Health Center
Farmington, Connecticut, United States - Psychiatric Medicine Associates, L.L.C.
Chicago, Illinois, United States - Massachusetts General Hosptial
Boston, Massachusetts, United States - (and 2 more...)
|
|
| 19 |
NCT00159146 |
Terminated |
Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression |
|
- Drug: Pindolol and venlafaxin
|
Interventional
|
Not Applicable |
- Hillerod Hospital, Denmark
- Wyeth is now a wholly owned subsidiary of Pfizer
- Tvergaards Foundation
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale scores
- Preskorn scores
|
31 |
All |
18 Years and older (Adult, Older Adult) |
NCT00159146 |
version 5 |
|
August 2002 |
|
September 2007 |
September 12, 2005 |
December 27, 2007 |
|
- Psychiatric Research Unit, Hillerod Hospital
Hillerod, Denmark
|
|
| 20 |
NCT01734291 |
Completed |
Brief Multifamily Psychoeducation for Families of Patients With Chronic Major Depression |
- Major Depressive Disorder
|
- Behavioral: Family psychoeducation
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The change of total score of K6 of family members
- The change of total score of Family Attitude Scale(FAS) of family members
|
49 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT01734291 |
NCUPsychiatricNursing001
ID24593499 |
|
October 1, 2012 |
June 20, 2016 |
October 9, 2016 |
November 27, 2012 |
April 5, 2017 |
|
- Fujika Katsuki
Nagoya, Aichi, Japan
|
|
| 21 |
NCT00149071 |
Completed |
Transcranial Magnetic Stimulation (rTMS) Accelerates the Response to Escitalopram in Major Depression |
|
|
Interventional
|
Not Applicable |
- Hillerod Hospital, Denmark
- Medicon Valley Academy
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
61 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00149071 |
1,2 |
|
March 2004 |
|
January 2006 |
September 8, 2005 |
November 5, 2007 |
|
- Psychiatric research unit, Hilleroed Hospital,
Hillerod, Denmark
|
|
| 22 |
NCT02165449 |
Recruiting |
Biomarkers of Fast Acting Therapies in Major Depression |
- Major Depressive Disorder
|
|
Interventional
|
Phase 1 |
- University of California, Los Angeles
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Hamilton Depression Rating Scale measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions
- Change in the Hamilton Depression Rating Scale measured between the last ketamine infusion treatment and 5 week follow-up
- Change in gene expression measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions
- (and 7 more...)
|
60 |
All |
18 Years to 64 Years (Adult) |
NCT02165449 |
HS001796
K24MH102743
U01MH110008 |
|
June 2014 |
August 2020 |
August 2021 |
June 17, 2014 |
August 28, 2018 |
|
- Geffen School of Medicine, UCLA
Los Angeles, California, United States
|
|
| 23 |
NCT01944657 |
Withdrawn |
Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study |
- 1. Major Depressive Disorder
|
- Device: Supplemental TMS
- Drug: Standard Medication Monotherapy
|
Interventional
|
Not Applicable |
- Sheppard Pratt Health System
- Central Michigan University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Montgomery-Åsberg Depression Rating Scale (MADRS)
- Hamilton Rating Scale for Depression (HRSD)
|
0 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01944657 |
SPHS IRB [354612-3] |
|
September 2013 |
December 2015 |
December 2015 |
September 18, 2013 |
April 25, 2017 |
|
- Sheppard Pratt Health System
Towson, Maryland, United States
|
|
| 24 |
NCT00220623 |
Unknown † |
Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression |
|
- Drug: antidepressant medications, flexible drug choice
- Behavioral: CBT, Psychodynamic or Supportive Psychotherapy
|
Interventional
|
Phase 3 |
- Sir Mortimer B. Davis - Jewish General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single
- Primary Purpose: Treatment
|
- Time to recovery of major depressive episode
- Time to recurrence of major depression, once recovered
- improvement in depressive defenses
- (and 3 more...)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00220623 |
#04-013 |
|
August 2004 |
|
|
September 22, 2005 |
September 22, 2005 |
|
- Institute of Community and Family Psychiatry
Montreal, Quebec, Canada
|
|
| 25 |
NCT00863798 |
Completed
Has Results |
Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Desvenlafaxine Succinate Sustained-Release 10mg
- Drug: Desvenlafaxine Succinate Sustained-Release 50 mg
- Drug: placebo
|
Interventional
|
Phase 3 |
- Wyeth is now a wholly owned subsidiary of Pfizer
- Pfizer
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in HAM-D17 Total Score at Final On-therapy (FOT) Evaluation (Week 8 or ET)
- Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) at FOT Evaluation (Week 8 or ET)
- Change From Baseline in Mean CGI-S Score at FOT Evaluation (Week 8 or ET)
- (and 6 more...)
|
682 |
All |
18 Years and older (Adult, Older Adult) |
NCT00863798 |
3151A1-3362
B2061005
3151A1-3362-US |
|
April 2009 |
March 2010 |
March 2010 |
March 18, 2009 |
May 6, 2011 |
May 6, 2011 |
- Pfizer Investigational Site
Birmingham, Alabama, United States - Pfizer Investigational Site
Encino, California, United States - Pfizer Investigational Site
Newport Beach, California, United States - (and 21 more...)
|
|
| 26 |
NCT00472576 |
Completed
Has Results |
Antidepressant Effects of NR2B in Major Depression |
|
- Drug: MK-0657
- Drug: Placebo
|
Interventional
|
Phase 1 |
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Hamilton Depression Rating Scale (HDRS)
|
5 |
All |
18 Years to 55 Years (Adult) |
NCT00472576 |
070152
07-M-0152 |
|
May 2007 |
August 2009 |
August 2009 |
May 11, 2007 |
August 3, 2012 |
April 7, 2011 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 27 |
NCT01579942 |
Terminated |
Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression |
- Major Depressive Disorder
|
|
Observational
|
|
- Massachusetts General Hospital
- ElMindA Ltd
|
Other / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Brain Network Analysis group patterns
- Identify possible predictors of treatment response
|
70 |
All |
18 Years to 55 Years (Adult) |
NCT01579942 |
2011P000200 |
|
April 2012 |
|
|
April 18, 2012 |
March 6, 2017 |
|
- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
|
| 28 |
NCT00798707 |
Completed
Has Results |
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)
- Drug: placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in HAM-D17 Total Score at the Final On-therapy (FOT)Evaluation (Week 8 or ET)
- Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) at FOT Evaluation (Week 8 or ET)
- Change From Baseline in Mean CGI-S Score at FOT Evaluation (Week 8 or ET)
- (and 6 more...)
|
709 |
All |
18 Years and older (Adult, Older Adult) |
NCT00798707 |
3151A1-3359
B2061003
3151A1-3359-WW |
|
December 2008 |
April 2010 |
April 2010 |
November 26, 2008 |
June 10, 2011 |
June 6, 2011 |
- Pfizer Investigational Site
Arcadia, California, United States - Pfizer Investigational Site
Beverly Hills, California, United States - Pfizer Investigational Site
Cerritos, California, United States - (and 75 more...)
|
|
| 29 |
NCT00419003 |
Completed
Has Results |
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications |
|
- Drug: Lamotrigine
- Drug: Ketamine
- Drug: Riluzole
|
Interventional
|
Phase 4 |
- Baylor College of Medicine
- National Alliance for Research on Schizophrenia and Depression
- National Center for Research Resources (NCRR)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MARDS) Score (Acute Response to IV Ketamine in Patients With Treatment Resistant Major Depression)
- Efficacy of Lamotrigine in Decreasing IV Ketamine Psychotomimetic Side Effects
|
26 |
All |
21 Years to 70 Years (Adult, Older Adult) |
NCT00419003 |
05-0850
5M01RR000071-46 |
|
December 2006 |
July 2008 |
September 2008 |
January 5, 2007 |
March 21, 2016 |
March 21, 2016 |
- Mount Sinai School of Medicine
New York, New York, United States
|
|
| 30 |
NCT00208156 |
Completed |
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression |
- Depressive Disorder, Major
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the safety and tolerability of Corlux (mifepristone) for the treatment of recurrent psychotic symptoms with major depression with psychotic features (PMD) who previously participated in Corcept Therapeutics Protocol C-1073-07
- To assess the frequency of retreatment with Corlux in patients with PMD and qualitatively describe the psychotic symptoms for which retreatment is clinically indicated
|
87 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00208156 |
C-1073-10 |
|
May 2005 |
November 2006 |
November 2006 |
September 21, 2005 |
February 15, 2012 |
|
- Cnri, Llc
San Diego, California, United States - Atlanta Center for Medical Research
Atlanta, Georgia, United States - Robert Horne M.D.
Las Vegas, Nevada, United States - (and 10 more...)
|
|
| 31 |
NCT00427128 |
Completed |
Prozac Treatment of Major Depression: Discontinuation Study |
|
- Drug: fluoxetine
- Drug: placebo
|
Interventional
|
Phase 4 |
- New York State Psychiatric Institute
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- MDD section of Mood Disorders Module of Structured Clinical Interview for DSM-IV (SCID)
- Ham-D
- CGI
|
627 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00427128 |
4099R
RO1 MH56058 |
|
November 1995 |
|
March 2003 |
January 26, 2007 |
December 15, 2011 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - New York State Psychiatric Institute
New York, New York, United States
|
|
| 32 |
NCT03347487 |
Recruiting |
Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression |
- Treatment Resistant Major Depression Disorder
|
- Procedure: Surgical Intervention
- Device: Shame DBS device followed by active DBS
- Device: Active DBS device followde by shame DBS
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- changes in the Hamilton Depression Scale(HAMD-17)
- changes in the Montgomery-Asberg Depression Rating Scale
- changes in the brain activity
- (and 4 more...)
|
6 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03347487 |
Habenula |
|
November 13, 2017 |
November 30, 2018 |
November 30, 2018 |
November 20, 2017 |
March 2, 2018 |
|
- Shanghai Ruijin Hospital Functional Neurosurgery
Shanghai, Shanghai, China
|
|
| 33 |
NCT01418638 |
Unknown † |
The Metabolic Effects of Antidepressants in Patients Diagnosed With Major Depressive Disorder |
- Major Depressive Disorder
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- the influence of antidepressant medications on the metabolic profiles (5) of patients suffering from Major Depressive Disorder.
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01418638 |
01-11 ZIV |
|
May 2012 |
October 2013 |
|
August 17, 2011 |
February 20, 2013 |
|
|
|
| 34 |
NCT00229645 |
Completed |
A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety |
- Major Depression With Comorbid Anxiety Symptoms
|
- Drug: Quetiapine Fumarate (Seroquel®)
|
Interventional
|
Phase 4 |
- Dr Alexander McIntyre Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To compare the efficacy of quetiapine versus placebo over 8 weeks as an adjunctive agent for unipolar non-psychotic adult outpatients on SSRI or SNRI therapy with residual symptoms of depression and comorbid anxiety symptoms. This will be measured by the
- 1. Hamilton Depression Scale (HAM-D) total score,
- 2. Hamilton Anxiety Scale (HAM-A) total score
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00229645 |
D1441C00017 |
|
November 2003 |
|
April 2005 |
September 30, 2005 |
July 13, 2016 |
|
- Dr. A. McIntyre
Penticton, British Columbia, Canada
|
|
| 35 |
NCT03514810 |
Completed |
Combined Sertraline and Ketoprofen Administration in Major Depressive Disorder |
- Major Depressive Disorder
|
- Combination Product: Combined Sertraline & Ketoprofen
- Other: Interleukins in MDD after treatment
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Reduction in the Beck Depression Inventory-II Score
- Decrease in Serum of IL-1β, IL-6, and IL-18 Levels
- Body mass index (BMI)
|
28 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03514810 |
KufaU
Arafataldujaili |
Srt+ktpMDD |
January 10, 2017 |
September 10, 2017 |
December 31, 2017 |
May 2, 2018 |
May 2, 2018 |
|
|
|
| 36 |
NCT00714779 |
Completed |
Fluoxetine vs. Brief Psychotherapy for Major Depression |
- Major Depressive Disorder
|
- Drug: Fluoxetine
- Behavioral: Short-term psychodynamic psychotherapy
|
Interventional
|
Not Applicable |
- University of Turku
- KELA
- Finnish State Grant
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
85 |
All |
20 Years to 60 Years (Adult) |
NCT00714779 |
HK123 |
|
January 2000 |
December 2004 |
December 2004 |
July 14, 2008 |
July 14, 2008 |
|
|
|
| 37 |
NCT00944996 |
Completed |
Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression |
|
|
Interventional
|
Not Applicable |
- Tirat Carmel Mental Health Center
- University of Michigan
- Ariel University
- The Nazareth Hospital, Israel
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Measurements of PACAP and BDNF serum levels
- Analysis of genetic variants of PACAP and PAC1 coding and regulatory regions
|
100 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00944996 |
akparl08
920080174
040-2008 |
|
June 2009 |
June 2010 |
July 2012 |
July 23, 2009 |
July 26, 2012 |
|
- Tirat Carmel Mental Health Center
Tirat Hacarmel, Israel
|
|
| 38 |
NCT01824433 |
Completed |
Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression |
|
- Drug: venlafaxine
- Drug: fluoxetine
|
Interventional
|
Phase 4 |
- Capital Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall Improvement
- Improvement of individual symptoms
|
189 |
Female |
50 Years to 80 Years (Adult, Older Adult) |
NCT01824433 |
VFPWMDD |
|
March 7, 2013 |
March 16, 2017 |
March 16, 2017 |
April 4, 2013 |
September 14, 2017 |
|
- Beijing Anding Hospital
Beijing, Beijing, China
|
|
| 39 |
NCT03295708 |
Recruiting |
Fish Oil as Adjunct Treatment for Major Depressive Disorder |
- Major Depressive Disorder
|
- Dietary Supplement: fish oil capsule
- Dietary Supplement: soybean oil capsule
|
Interventional
|
Not Applicable |
- Second Xiangya Hospital of Central South University
- Xiangya Hospital of Central South University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Changes in Hamilton Depression Scale (HAMD) HAMD
- Changes in Clinical Global Impression (CGI)
- Changes in Hamilton Anxiety Scale (HAMA)
- (and 2 more...)
|
120 |
All |
18 Years to 50 Years (Adult) |
NCT03295708 |
MDD201610 |
|
October 1, 2017 |
October 1, 2019 |
April 1, 2020 |
September 28, 2017 |
October 10, 2017 |
|
- Mental Health Institute, Second Xiangya Hospital of Central South University
Changsha, Hunan, China
|
|
| 40 |
NCT01450150 |
Unknown † |
Transcranial Direct Current Stimulation as an Augmenting Intervention for Major Depression |
- Major Depressive Disorder
|
- Device: Transcranial Direct Current Stimulation
|
Interventional
|
Phase 2
Phase 3 |
- Douglas Mental Health University Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C)
- 21-item Hamilton Depression Rating Scale (HAM-D21)
- Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR)
|
30 |
All |
18 Years to 60 Years (Adult) |
NCT01450150 |
tDCS-ERB08/04-2011 |
|
January 2016 |
October 2018 |
October 2018 |
October 12, 2011 |
January 20, 2016 |
|
- Douglas Mental Health University Institute
Montreal, Quebec, Canada
|
|
| 41 |
NCT03254017 |
Recruiting |
Remotely Programmed Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression: An Open Label Pilot Trial |
- Treatment Resistant Major Depressive Disorder
|
- Procedure: Bilateral surgical implantation of DBS system to Habeluna
- Other: Follow-up Period
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Montgomery-Asberg Depression Rating Scale
- Change in the Hamilton Depression Scale
- Change in the Hamilton Anxiety Scale
- (and 5 more...)
|
6 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03254017 |
Habenula DBS |
|
July 24, 2017 |
July 30, 2018 |
August 30, 2019 |
August 18, 2017 |
May 18, 2018 |
|
- Shanghai Ruijin Hospital Functional Neurosurgery
Shanghai, Shanghai, China - Shanghai Ruijin Hospital Functional Neurosurgery
Shanghai, Shanghai, China
|
|
| 42 |
NCT00489775 |
Completed |
Duloxetine Versus Paroxetine for Major Depression |
- Major Depressive Disorder
|
- Drug: Duloxetine
- Drug: Paroxetine
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To assess hypothesis that efficacy of duloxetine 60mg QD is non-inferior to paroxetine 20mg QD in treating major depressive disorder as defined by DSM-IV. Primary efficacy evaluated by mean change of HAMD17 total scores from baseline to endpoint.
- To compare the efficacy of duloxetine 60 mg QD and paroxetine 20 mg QD on anxiety symptoms associated with depression as measured by mean changes in Hamilton Anxiety Rating Scale (HAMA) total scores
- To compare efficacy of treatment with duloxetine 60 mg QD and paroxetine 20 mg QD on symptoms of depression measured by mean endpoint scale on the Clinical Global Impression of Severity Scale (CGI-S) scale and the endpoint score
- (and 4 more...)
|
480 |
All |
18 Years and older (Adult, Older Adult) |
NCT00489775 |
6937
F1J-AA-HMCV |
|
January 2004 |
|
June 2005 |
June 21, 2007 |
June 21, 2007 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Beijing, China
|
|
| 43 |
NCT00510822 |
Completed |
Cimicoxib for the Treatment of Major Depression (SECIM) |
|
- Drug: Cimicoxib
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Affectis Pharmaceuticals AG
- FGK Clinical Research GmbH
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- • Mean change on the total score of the Hamilton Depression Rating Scale (HamD-17) from baseline to endpoint (Week 6).
- • Changes from baseline to interim weekly visits (week 1 to 5) in HamD-17 score • Clinical Global Impression (CGI) score • Montgomery Asberg Depression Rating Scale (MADRS) score • Response rate, remission rate and drop out rate. • Onset of
|
169 |
All |
18 Years to 60 Years (Adult) |
NCT00510822 |
AFX-01
EudraCT-No. 2007-001335-54 |
|
October 2007 |
February 2010 |
February 2010 |
August 2, 2007 |
November 13, 2013 |
|
- Landeskrankenhaus Klagenfurt, Abteilung für Psychiatrie und Psychotherapie
Klagenfurt, Austria - Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft mbH
Salzburg, Austria - Faculty Hospital Brno
Brno, Czech Republic - (and 22 more...)
|
|
| 44 |
NCT01741142 |
Terminated |
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: ABT-436
- Drug: Escitalopram
- Drug: Placebo
|
Interventional
|
Phase 2 |
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Primary efficacy variable will be change from baseline to Week 6 visit on Montgomery-Asberg Depression Rating Scale (MADRS) total score.
- Secondary efficacy variables include change from Baseline to Week 6 on clinician-rated Hamilton Depression Rating Scale.
|
19 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01741142 |
M11-733 |
|
January 2012 |
October 2013 |
August 2015 |
December 4, 2012 |
October 8, 2013 |
|
- Site Reference ID/Investigator# 85593
Little Rock, Arkansas, United States - Site Reference ID/Investigator# 87228
Garden Grove, California, United States - Site Reference ID/Investigator# 87214
National City, California, United States - (and 15 more...)
|
|
| 45 |
NCT00125554 |
Completed |
Metyrapone as Additive Treatment in Major Depression |
- Major Depressive Disorder
|
|
Interventional
|
Phase 2 |
- Universitätsklinikum Hamburg-Eppendorf
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Two psychometric criteria defined by the number of responders and time to onset-of-action. The number of responders was considered twice after 3 and 5 weeks by defining the treatment response as a 30% and 50% reduction
- the course of concentrations of ACTH, cortisol, 11-deoxycortisol and DHEA.
- Other psychometric scores, demographic parameters and side effects were considered as secondary variables.
|
63 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00125554 |
HH-PSY-ja-007 |
|
May 1998 |
|
July 2001 |
August 1, 2005 |
August 12, 2005 |
|
- Dept. of Psychiatry and Psychotherapy, UKE
Hamburg, Germany
|
|
| 46 |
NCT02484456 |
Recruiting |
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder |
|
- Drug: AV 101 (4-Chlorokynurenine)
- Other: Placebo
|
Interventional
|
Phase 2 |
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in the Hamilton Depression Rating scale total score.
- Change from baseline in BPRS, CADSS, C-SSRS, HAM-A, HDRS, MADRS, PANAS, SHAPS, SSI, TEPS, YMRS total scores.
- Change from baseline in the C-SSRS total score.
- (and 3 more...)
|
25 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02484456 |
150151
15-M-0151 |
|
June 19, 2015 |
December 31, 2019 |
December 31, 2019 |
June 29, 2015 |
October 19, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 47 |
NCT02489305 |
Completed |
Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD) |
- Depressive Disorder, Major
|
|
Observational
|
|
- Janssen Research & Development, LLC
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of Participants With Near Term Relapse
|
330 |
All |
18 Years to 64 Years (Adult) |
NCT02489305 |
CR105160
OBSERVEMDD0001 |
|
December 15, 2014 |
May 1, 2018 |
May 1, 2018 |
July 3, 2015 |
October 26, 2018 |
|
- Birmingham, Alabama, United States
- Glendale, California, United States
- Oceanside, California, United States
- (and 22 more...)
|
|
| 48 |
NCT03012724 |
Recruiting |
Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD) |
- Major Depressive Disorder (MDD)
|
- Device: H7-Coil
- Device: H1-Coil
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- HDRS-21 Score Change From Baseline
- Response Rate in HDRS-21
- Remission Rate
|
106 |
All |
22 Years to 68 Years (Adult, Older Adult) |
NCT03012724 |
CTP-0001-01 |
|
March 30, 2017 |
January 2019 |
April 2019 |
January 6, 2017 |
April 10, 2018 |
|
- Kadima Neuropsychiatry
La Jolla, California, United States - Advanced Mental Health Care Inc. - Juno Beach
Juno Beach, Florida, United States - Advanced Mental Health Care Inc. - Palm Beach
Palm Beach, Florida, United States - (and 5 more...)
|
|
| 49 |
NCT00531947 |
Completed
Has Results |
Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression |
- Major Depressive Disorder
|
- Drug: Selegiline Transdermal System
- Drug: Placebo
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- CDRS-R Total Score (Child) (mITT w/LOCF Population) Week 12
- CGI-S - Week 12 (mITT w/LOCF Population)
- CGI-C - Week 12 (mITT w/LOCF Population)
- (and 16 more...)
|
308 |
All |
12 Years to 17 Years (Child) |
NCT00531947 |
S9303-P0605 |
|
July 2007 |
October 2010 |
October 2010 |
September 19, 2007 |
January 15, 2014 |
June 26, 2013 |
- Dr. Nelson Handal
Dothan, Alabama, United States - Dr. Mohammed Bari
National City, California, United States - Dr. Michael McManus
SanDiego, California, United States - (and 17 more...)
|
|
| 50 |
NCT02793258 |
Recruiting |
Impact of tDCS on Emotional Processing in Major Depression |
- Major Depressive Disorder
|
- Device: transcranial direct current stimulation
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of correct responses at a facial expression recognition task
- Evolution of the depressive symptoms measured by MADRS
- Performance on an attentional dot-probe task
- (and 7 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02793258 |
2016-A00415-46 |
EmoStim |
July 22, 2016 |
January 2019 |
June 2019 |
June 8, 2016 |
August 2, 2018 |
|
- Ch Le Vinatier
Lyon, Rhone Alpes, France
|
|
| 51 |
NCT01473381 |
Completed
Has Results |
Safety and Efficacy of Vilazodone in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Vilazodone
- Drug: Placebo to citalopram
- Drug: Placebo to vilazodone
- Drug: Citalopram
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 10
- Change From Baseline to Week 10 in the Clinical Global Impressions-Severity (CGI-S) Scale Score
- Percentage of Participants With a Montgomery-Åsberg Depression Rating Scale (MADRS) Sustained Response
|
1162 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01473381 |
VLZ-MD-01 |
VLZ-MD-01 |
December 2011 |
June 2013 |
June 2013 |
November 17, 2011 |
August 8, 2014 |
August 8, 2014 |
- Forest Investigative Site 036
Birmingham, Alabama, United States - Forest Investigative Site 016
Dothan, Alabama, United States - Forest Investigative Site 033
Scottsdale, Arizona, United States - (and 51 more...)
|
|
| 52 |
NCT01685294 |
Completed |
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression |
- Major Depressive Disorder
|
- Behavioral: Group IPT for Depression + TAU
|
Interventional
|
Phase 3 |
- Brown University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline in Hamilton Rating Scale for Depression (HRSD) at 3 Months
- Change from Baseline in Suicidality at 3 Months
- Change from Baseline in In-Prison Functioning at 3 Months
- (and 4 more...)
|
181 |
All |
18 Years and older (Adult, Older Adult) |
NCT01685294 |
1R01MH095230-01
R01MH095230 |
|
December 2011 |
October 2014 |
October 2014 |
September 14, 2012 |
January 13, 2016 |
|
- Massachusetts Correctional Institute - Old Colony Correctional Center
Bridgewater, Massachusetts, United States - Massachusetts Correctional Institution - Framingham
Framingham, Massachusetts, United States - South Middlesex Correctional Center
Framingham, Massachusetts, United States - (and 2 more...)
|
|
| 53 |
NCT00461279 |
Completed |
Attachment Security as Mediator and Moderator of Outcome in Major Depression |
|
- Behavioral: Cognitive Behavior Therapy
- Behavioral: Interpersonal Psychotherapy
|
Interventional
|
Not Applicable |
- Centre for Addiction and Mental Health
- Ontario Mental Health Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
134 |
All |
18 Years and older (Adult, Older Adult) |
NCT00461279 |
165/2006 |
|
August 2006 |
February 2010 |
March 2010 |
April 17, 2007 |
December 6, 2011 |
|
- Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 54 |
NCT01473394 |
Completed
Has Results |
Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Dose-matched placebo
- Drug: Vilazodone
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8
- Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score at Week 8
- Percentage of Participants With a Montgomery-Åsberg Depression Rating Scale (MADRS) Sustained Response Rate
|
518 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01473394 |
VLZ-MD-03 |
|
December 2011 |
February 2013 |
February 2013 |
November 17, 2011 |
April 3, 2014 |
April 3, 2014 |
- Forest Investigative Site 009
Beverly Hills, California, United States - Forest Investigative Site 003
Encino, California, United States - Forest Investigative Site 010
New port Beach, California, United States - (and 11 more...)
|
|
| 55 |
NCT00351169 |
Completed |
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Quetiapine SR
- Drug: Escitalopram
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To evaluate the efficacy of quetiapine SR compared with placebo in the treatment of patients with major depressive disorder (MDD) as assessed by change from randomisation to week 8 score in the MADRS total score.
- If quetiapine SR improves health-related quality of life of patients with MDD, compared to placebo
|
450 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00351169 |
D1448C00004
AMBER
EUDRACT No: 2005-005052-40 |
AMBER |
May 2006 |
|
June 2007 |
July 12, 2006 |
December 22, 2008 |
|
- Research Site
Edmonton, Alberta, Canada - Research Site
Kelowna, British Columbia, Canada - Research Site
Penticton, British Columbia, Canada - (and 39 more...)
|
|
| 56 |
NCT01838876 |
Completed |
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
|
Interventional
|
Phase 3 |
- Forest Laboratories
- Gedeon Richter Ltd.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and Tolerability in patients with Major Depressive Disorder (assessments w ill include adverse events, clinical laboratory parameters, vital signs, Electrocardiograms, Extra Pyramidal Symptom (EPS) scales, and ophthalmologic examination)
|
442 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01838876 |
RGH-MD-76 |
|
April 29, 2013 |
July 27, 2015 |
July 27, 2015 |
April 24, 2013 |
March 12, 2018 |
|
- Forest Investigative Site 032
Tucson, Arizona, United States - Forest Investigative Site 109
Tucson, Arizona, United States - Forest Investigative Site 105
Fayetteville, Arkansas, United States - (and 87 more...)
|
|
| 57 |
NCT01426997 |
Completed |
Phenotype Depression Study |
- Major Depressive Disorder
|
|
Observational
|
|
- Emory University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- We are using clinician administered and self report psychiatric measurements to compare relevant symptom domains in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.
- We are measuring immune markers for the identification of relevant immunologic patterns of activation in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.
|
279 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT01426997 |
IRB00039107
1R01MH087604-01A1 |
|
July 2010 |
May 2016 |
May 2016 |
September 1, 2011 |
June 22, 2016 |
|
- Emory University Department of Psychiatry and Behavioral Sciences
Atlanta, Georgia, United States
|
|
| 58 |
NCT00278941 |
Completed |
Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Quetiapine Fumarate Sustained Release
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to a depressed event in patients with Major Depressive Disorder (MDD)
- Evaluate quetiapine SR compared to placebo on health related quality of life.
|
3000 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00278941 |
D1448C00005
Amethyst |
AMETHYST |
December 2005 |
|
August 2007 |
January 19, 2006 |
March 25, 2009 |
|
- Research Site
Birmingham, Alabama, United States - Research Site
Tuscaloosa, Alabama, United States - Research Site
Mesa, Arizona, United States - (and 165 more...)
|
|
| 59 |
NCT00289484 |
Unknown † |
A Study of Omega-3 as an Augmentor of Antidepressant Treatment for Major Depression |
|
- Drug: Omega-3 Polyunsaturated Fatty Acids
|
Interventional
|
Phase 2 |
- The University of New South Wales
- Your Health Inc.
- Sphere Healthcare
- Ocean Nutrition
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Change form pretreatment score on Depression Rating scale at 4 weeks
- Daily mood rating
- Weekly measure of depression
- (and 2 more...)
|
52 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00289484 |
05156 |
|
February 2006 |
|
|
February 9, 2006 |
September 13, 2006 |
|
- The University of New South Wales/Black Dog Institute
Sydney, New South Wales, Australia
|
|
| 60 |
NCT03632434 |
Not yet recruiting |
Transcranial Direct Current Stimulation Therapy for Major Depression |
- Major Depressive Disorder
|
- Device: transcranial direct current stimulation
|
Interventional
|
Not Applicable |
- University of East London
- King's College London
- University of Oxford
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
30 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03632434 |
A1950 |
|
February 2019 |
November 2020 |
November 2020 |
August 15, 2018 |
August 15, 2018 |
|
|
|
| 61 |
NCT03421574 |
Recruiting |
Trial of MR-guided Focused Ultrasound for Treatment of Refractory Major Depression |
- Major Depressive Disorder
|
- Device: MR-guided Focused Ultrasound
|
Interventional
|
Not Applicable |
- Sunnybrook Health Sciences Centre
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Treatment-Emergent Adverse Events
- Quality of Life will be measured using the Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ)
- Clinical efficacy will be measured using the Hamilton Rating Scale for Depression (HAMD)
- (and 3 more...)
|
12 |
All |
20 Years to 80 Years (Adult, Older Adult) |
NCT03421574 |
344-2017 |
|
January 19, 2018 |
December 7, 2018 |
December 7, 2018 |
February 5, 2018 |
August 6, 2018 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
|
|
| 62 |
NCT01999010 |
Completed |
Mental Health Telemetry for Self-Management in Major Depression |
- Major Depressive Disorder
|
|
Interventional
|
Not Applicable |
- Sunnybrook Health Sciences Centre
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in self-management ratings
- Change in Quality-of-life (QoL) ratings
|
27 |
All |
14 Years and older (Child, Adult, Older Adult) |
NCT01999010 |
186-2013 |
MHTV |
November 2014 |
April 2016 |
April 2016 |
December 3, 2013 |
January 5, 2017 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
|
|
| 63 |
NCT00285766 |
Completed |
Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression |
|
- Drug: Selegiline Transdermal System
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
300 |
All |
65 Years and older (Older Adult) |
NCT00285766 |
S9303-P0204 |
|
August 2002 |
|
July 2005 |
February 2, 2006 |
April 22, 2008 |
|
- Mohammed Bari, M.D.
Chula Vista, California, United States - Charles Meredith, M.D.
San Diego, California, United States - Daniel Zimbroff, M.D.
Upland, California, United States - (and 12 more...)
|
|
| 64 |
NCT00067301 |
Completed |
PUFA Augmentation in Treatment of Major Depression |
|
- Drug: Polyunsaturated Fatty Acids (PUFA)
- Drug: Citalopram
|
Interventional
|
Phase 3 |
- National Center for Complementary and Integrative Health (NCCIH)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00067301 |
R21AT001077
GertsikL |
|
September 2003 |
April 2007 |
April 2007 |
August 15, 2003 |
January 25, 2008 |
|
- Cedars-Sinai Medical Center Dept. of Psychiatry
Los Angeles, California, United States
|
|
| 65 |
NCT02176408 |
Unknown † |
Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression |
- Major Depressive Disorder
|
- Behavioral: Behavioral Activation
- Behavioral: Exercise Intervention
- Behavioral: Stretching Intervention
|
Interventional
|
Not Applicable |
- Boston University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Beck Depression Inventory-II (BDI-II)
- Work and Social Adjustment Scale (WSAS)
- (and 8 more...)
|
38 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02176408 |
F31MH100773-01A1 |
|
June 2014 |
June 2016 |
June 2016 |
June 27, 2014 |
April 6, 2016 |
|
- Boston University
Boston, Massachusetts, United States
|
|
| 66 |
NCT00887224 |
Completed
Has Results |
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Desvenlafaxine succinate sustained release 50 mg
- Drug: Desvenlafaxine succinate sustained release 25 mg
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185
- Number of Participants Per Categorical Score for Change From Baseline on Clinical Global Impression-Improvement (CGI-I) Scale
- Change From Baseline in Clinical Global Impression-Severity of Illness [CGI-S] Score in the Double-blind Phase
- (and 5 more...)
|
874 |
All |
18 Years and older (Adult, Older Adult) |
NCT00887224 |
3151A1-3360
B2061004 |
|
June 2009 |
March 2011 |
March 2011 |
April 23, 2009 |
November 21, 2014 |
June 27, 2012 |
- Pfizer Investigational Site
Beverly Hills, California, United States - Pfizer Investigational Site
Encino, California, United States - Pfizer Investigational Site
Los Alamitos, California, United States - (and 86 more...)
|
|
| 67 |
NCT02086929 |
Completed |
Trazodone Once a Day in Major Depression Disorder |
- Major Depressive Disorder
|
- Drug: Trazodone
- Drug: Venlafaxine
|
Interventional
|
Phase 3 |
- Aziende Chimiche Riunite Angelini Francesco S.p.A
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale (HAMD) score
- Montgomery-Asberg Depression Rating Scale (MADRS) score
- Clinical Global Impression (CGI) Severity of Illness score
- (and 4 more...)
|
364 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02086929 |
039(C)SC11063 |
|
December 2012 |
April 2014 |
April 2014 |
March 13, 2014 |
December 30, 2015 |
|
- Institute für Psychosomatik
Vienna, Austria - AKH Wien
Vienna, Austria - PRAGTIS, s.r.o.
Praha 2, Praha, Czech Republic - (and 29 more...)
|
|
| 68 |
NCT00715559 |
Terminated
Has Results |
Cysteamine Therapy for Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: cysteamine bitartrate
|
Interventional
|
Not Applicable |
- Icahn School of Medicine at Mount Sinai
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Montgomery-Åsberg Depression Rating Scale (MADRS)
- Clinical Global Impression Scales for Severity (CGI-S) and Improvement (CGI-I)
- Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16)
- Systematic Assessment for Treatment Emergent Effects (SAFTEE)
|
3 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00715559 |
GCO # 07-0478 |
|
July 2008 |
May 2009 |
May 2009 |
July 15, 2008 |
April 7, 2017 |
June 16, 2011 |
- Mount Sinai School of Medicine
New York, New York, United States
|
|
| 69 |
NCT00770783 |
Completed |
Magnetic Seizure Therapy (MST) for Treatment Resistant Major Depression |
|
- Device: Thymatron
- Device: Tonica MagPro MST
|
Interventional
|
Phase 3 |
- University Hospital, Bonn
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Clinical improvement (Hamilton Rating Scale for Depression)
- Clinical improvement (Montgomery- Åsberg Rating Scale for Depression)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00770783 |
BSG-05-001 |
|
February 2005 |
September 2013 |
May 2014 |
October 10, 2008 |
August 6, 2018 |
|
- Department of Psychiatry and Psychotherapy - University Hospital
Bonn, Germany
|
|
| 70 |
NCT02047968 |
Completed |
Wake and Light Therapy to In-patients With Major Depression: Efficacy, Predictors and Patient Experiences |
|
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Response
- Remission
- Length of admission
- (and 2 more...)
|
64 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02047968 |
VT12 |
|
February 2014 |
May 2016 |
May 2016 |
January 29, 2014 |
October 31, 2016 |
|
- Mette Kragh
Risskov, Central Denmark Region, Denmark
|
|
| 71 |
NCT01916824 |
Completed
Has Results |
Effects of Treatment on Decision-making in Major Depression |
- Major Depressive Disorder
- Healthy Controls
|
- Drug: Any FDA Approved Antidepressant
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
|
53 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01916824 |
IRB00066705 |
|
August 2013 |
December 2015 |
December 2015 |
August 6, 2013 |
November 21, 2017 |
October 20, 2017 |
- Emory Mood and Anxiety Disorders Program
Atlanta, Georgia, United States
|
|
| 72 |
NCT00351910 |
Completed |
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Quetiapine
- Drug: Amitriptyline
- Drug: Bupropion
- (and 7 more...)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To evaluate the efficacy of quetiapine fumarate sustained release
- (Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder.
- If quetiapine SR in combination with an antidepressant improves health-related quality of life of patients with MDD, compared to an antidepressant alone.
|
494 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00351910 |
D1448C00007
ONYX
EUDRACT No: 2005-0055053-22 |
ONYX |
May 2006 |
|
April 2007 |
July 13, 2006 |
January 26, 2011 |
|
- Research Site
Everton Park, Queensland, Australia - Research Site
Southport, Queensland, Australia - Research Site
Frankston, Victoria, Australia - (and 71 more...)
|
|
| 73 |
NCT02346682 |
Unknown † |
Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder |
- Severe Major Depression Disorder
|
|
Interventional
|
Phase 4 |
- Zhejiang Provincial Tongde Hospital
- The University of Hong Kong
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Brain neuroimaging
- Biochemical tests
|
75 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02346682 |
zjsltdyy2014009
8140151401 |
NMNTDM |
February 2015 |
June 2017 |
December 2017 |
January 27, 2015 |
April 27, 2015 |
|
- Tongde hospital of zhejiang province
Hangzhou, Zhejiang, China
|
|
| 74 |
NCT01778790 |
Completed |
Deep Brain Stimulation of the Superolateral Branch of the Medial Forebrain Bundle (slMFB) for the Treatment of Refractory Major Depression |
|
- Device: Deep Brain Stimulation with Activa PC Multi-program Neurostimulator
|
Interventional
|
Phase 2 |
- University Hospital, Bonn
|
Other |
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Depression Severity assessed with Montgomery Asberg Depression Scale (MADRS)
- Depression Severity rated with Hamilton Depression Rating Scale (HDRS24)
|
16 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT01778790 |
BSG-13-2319DBS |
FORESEEII |
July 2013 |
February 2016 |
January 2018 |
January 29, 2013 |
August 7, 2018 |
|
- University Hospital Bonn
Bonn, Germany
|
|
| 75 |
NCT00260468 |
Completed |
Brain Abnormalities in Late-Onset Major Depression |
|
- Other: Clinical examination program
|
Observational
|
|
- University of Aarhus
- The Danish Medical Research Council
- Bayer
|
Other / Industry |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
|
44 |
All |
50 Years and older (Adult, Older Adult) |
NCT00260468 |
20051050 |
|
November 2005 |
|
December 2008 |
December 1, 2005 |
October 22, 2009 |
|
- Centre for Psychiatric Research, Aarhus University Hospital
Risskov, Denmark
|
|
| 76 |
NCT03053830 |
Recruiting |
Open Label Ketamine Treatment for Major Depressive Disorder in Veterans |
- Major Depressive Disorder
|
|
Interventional
|
Phase 2 |
- VA Connecticut Healthcare System
|
U.S. Fed |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS)
- Change in Quick Inventory of Depressive Symptomatology-Self Report (QUIDS-SR)
- Change in Hamilton Anxiety Rating Scale (HAM-A)
- (and 8 more...)
|
25 |
All |
21 Years to 75 Years (Adult, Older Adult) |
NCT03053830 |
MR0012 |
Ket-MDD |
January 31, 2017 |
January 30, 2020 |
January 30, 2020 |
February 15, 2017 |
June 5, 2018 |
|
- VA Healthcare System
West Haven, Connecticut, United States
|
|
| 77 |
NCT02934334 |
Active, not recruiting |
Wellness Monitoring for Major Depressive Disorder |
- Major Depressive Disorder
|
|
Observational
|
|
- Sidney Kennedy
- University Health Network, Toronto
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Rate of MDD Patients with Near Term Relapse
|
100 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02934334 |
REB 15-9780-AE |
CBN-Well |
May 31, 2016 |
December 2018 |
January 2019 |
October 14, 2016 |
April 19, 2018 |
|
- University of Calgary
Calgary, Alberta, Canada - University of British Columbia
Vancouver, British Columbia, Canada - McMaster University
Hamilton, Ontario, Canada - (and 2 more...)
|
|
| 78 |
NCT03093025 |
Active, not recruiting |
A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: TS-121 10 mg
- Drug: TS-121 50 mg
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Taisho Pharmaceutical R&D Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Hamilton Anxiety Scale (HAM-A)
- Symptoms of Depression Questionnaire (SDQ)
- (and 2 more...)
|
180 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03093025 |
TS121-US201 |
|
July 3, 2017 |
November 2018 |
November 2018 |
March 28, 2017 |
August 8, 2018 |
|
- Woodland International Research Group
Little Rock, Arkansas, United States - Woodland Research Northwest
Rogers, Arkansas, United States - Collaborative Neuroscience Network
Garden Grove, California, United States - (and 19 more...)
|
|
| 79 |
NCT03487198 |
Recruiting |
The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Brexpiprazole
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Otsuka Beijing Research Institute
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in the MADRS Total Score
- Change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in SDS Mean Score
- Change from the end of Phase A (Week 8 visit) in MADRS Total Score for every trial week visit in Phase B other than Week 14 visit
- (and 8 more...)
|
1100 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03487198 |
331-403-00023 |
|
May 31, 2018 |
October 31, 2020 |
November 30, 2020 |
April 3, 2018 |
August 22, 2018 |
|
- Beijing Anding Hospital of Capital Medical University
Beijing, Beijing, China
|
|
| 80 |
NCT01573598 |
Completed |
Safety and Efficacy of Vilazodone in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Placebo
- Drug: Vilazodone
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to first relapse during the double-blind treatment phase
|
1219 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01573598 |
VLZ-MD-02 |
|
April 2012 |
October 2014 |
January 2015 |
April 9, 2012 |
May 18, 2015 |
|
- Forest Investigative Site 030
Beverly Hills, California, United States - Forest Investigative Site 012
Chino, California, United States - Forest Investigative Site 022
Costa Mesa, California, United States - (and 72 more...)
|
|
| 81 |
NCT01095263 |
Completed |
Effects of Deep Brain Stimulation in Treatment Resistant Major Depression |
|
- Device: DBS
- Device: No Stimulation (Sham)
|
Interventional
|
Phase 1 |
- University Hospital, Bonn
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Depression Severity assessed with Montgomery Asberg Depression Scale (MADRS)
- Depression Severity rated with Hamilton Depression Rating Scale (HDRS24)
- Adverse Event Schedule
- Comprehensive neuropsychological test battery
|
7 |
All |
20 Years to 70 Years (Adult, Older Adult) |
NCT01095263 |
BSG-10-4711DBS |
FORESEE |
April 2011 |
August 2012 |
January 2013 |
March 30, 2010 |
August 6, 2018 |
|
- University Hospital Bonn
Bonn, Germany
|
|
| 82 |
NCT00889369 |
Unknown † |
Duloxetine for Major Depression in Peri-/Postmenopausal Women |
- Major Depressive Disorder
|
|
Interventional
|
Phase 4 |
- Hamilton Health Sciences Corporation
- Eli Lilly and Company
- St. Joseph's Healthcare Hamilton
- McMaster University
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The effects of response to treatment with duloxetine on brain structure and activation in subjects (peri- and postmenopausal women with MDD).
- Changes in brain activation in remitters versus non-remitters after treatment with duloxetine (remission of depression defined MADRS total score <10 at study end).
- Correlations between changes in brain activation and changes from baseline to study end and menopausal symptoms, depressive symptoms, cognition, quality of life, and clinical global impression (improvement and severity).
|
70 |
Female |
40 Years to 60 Years (Adult) |
NCT00889369 |
WHCC2008-2 |
|
May 2009 |
February 2012 |
June 2012 |
April 28, 2009 |
February 8, 2012 |
|
- Women's Health Concerns Clinic
Hamilton, Ontario, Canada
|
|
| 83 |
NCT01754493 |
Completed
Has Results |
Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression |
- Major Depression
- Irritable Bowel Syndrome
|
|
Interventional
|
Phase 4 |
- New York State Psychiatric Institute
- Eli Lilly and Company
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Gastrointestinal Symptoms Rating Scale (GSRS)
- Clinician-Rated Global Impression Scales (CGI)
- (and 2 more...)
|
17 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01754493 |
#6479R
F1J-US-X037 |
IBS-MDD |
December 2008 |
December 2014 |
December 2014 |
December 21, 2012 |
November 25, 2016 |
November 25, 2016 |
- New York State Psychiatric Institute, 1051 Riverside Drive
New York, New York, United States
|
|
| 84 |
NCT00384033 |
Completed
Has Results |
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder |
- Depressive Disorder, Major
|
- Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)
- Drug: Placebo
- Drug: Duloxetine 60 mg/day
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in HAM-D17 Total Score at Week 8 or Final On-therapy (FOT) Evaluation
- Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) Score at Week 8 or FOT Evaluation
- Change From Baseline in Mean CGI-S Score at Week 8 or FOT Evaluation
- (and 6 more...)
|
638 |
All |
18 Years and older (Adult, Older Adult) |
NCT00384033 |
3151A1-335 |
|
September 2006 |
September 2007 |
September 2007 |
October 4, 2006 |
March 15, 2012 |
March 15, 2012 |
- Pfizer Investigational Site
Beverly Hills, California, United States - Pfizer Investigational Site
Burbank, California, United States - Pfizer Investigational Site
Encino, California, United States - (and 19 more...)
|
|
| 85 |
NCT00873795 |
Completed |
Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression |
- Major Depressive Disorder
|
- Drug: aripiprazole , sertraline
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- score change of Hamilton Rating Scale For Depression (HAM-D17 )
- score change of Brief Psychiatric Rating Scale (BPRS-50)
|
41 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00873795 |
IRB 09603-001 |
|
April 2007 |
March 2009 |
March 2009 |
April 2, 2009 |
April 2, 2009 |
|
- Psychiatry Department, Chimei Medical Center
Tainan, Taiwan
|
|
| 86 |
NCT01034267 |
Completed |
Safety Study of F2695 SR in Major Depressive Disorder |
- Major Depressive Disorder
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse events, clinical laboratory tests, vital sign measurements, electrocardiograms, physical examinations, Columbia-Suicide Severity Rating Scale
|
828 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01034267 |
LVM-MD-04 |
LVM-MD-04 |
December 2009 |
June 2012 |
|
December 17, 2009 |
August 17, 2012 |
|
- Forest Investigative Site 55
Dothan, Alabama, United States - Forest Investigative Site 29
Scottsdale, Arizona, United States - Forest Investigative Site 31
Beverly Hills, California, United States - (and 65 more...)
|
|
| 87 |
NCT01377194 |
Completed
Has Results |
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Levomilnacipran ER
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.
- Change in Sheehan Disability Scale (SDS) Total Score
|
568 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01377194 |
LVM-MD-10 |
|
June 2011 |
March 2012 |
March 2012 |
June 21, 2011 |
October 29, 2013 |
October 29, 2013 |
- Forest Investigative Site 039
Birmingham, Alabama, United States - Forest Investigative Site 037
Beverly Hills, California, United States - Forest Investigative Site 012
Encino, California, United States - (and 48 more...)
|
|
| 88 |
NCT01409317 |
Completed |
Neural Predictors and Longitudinal Neural Correlates of Deep Transcranial Magnetic Stimulation for Treating Major Depression |
- Major Depressive Disorder
|
- Device: Deep Transcranial Magnetic Stimulation
- Device: Repetitive Transcranial Magnetic Stimulation
|
Interventional
|
Phase 2
Phase 3 |
- Douglas Mental Health University Institute
- Brainsway
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- 21-item Hamilton Depression Rating Scale (HAM-D21)
- Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR)
|
10 |
All |
25 Years to 50 Years (Adult) |
NCT01409317 |
DTMS-ERB11/28-2011 |
|
April 2013 |
January 2015 |
January 2015 |
August 4, 2011 |
May 28, 2015 |
|
- Neuromodulation Research Clinic, Douglas Mental Health University Institute
Montreal, Quebec, Canada
|
|
| 89 |
NCT00102492 |
Completed |
Study Of GW679769 In Major Depressive Disorder |
- Depressive Disorder, Major
- Major Depressive Disorder (MDD)
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Change from baseline on the 17-item Hamilton Depression Rating Scale (HAM-D) total score at week 8, Last Observation Carried Forward.
- CGI, HAM-A, QUIDS, SDS, MOS-12 Sleep Module, LSEQ, Safety and Tolerability, PK/PD
|
356 |
All |
18 Years to 64 Years (Adult) |
NCT00102492 |
NKF100092 |
|
October 2004 |
September 2006 |
September 2006 |
January 31, 2005 |
April 16, 2015 |
|
- GSK Investigational Site
Scottsdale, Arizona, United States - GSK Investigational Site
Little Rock, Arkansas, United States - GSK Investigational Site
Beverly Hills, California, United States - (and 28 more...)
|
|
| 90 |
NCT01357083 |
Completed |
The Study of Serum Melatonin Rhythm Levels in Patients With Major Depressive Disorder |
- Major Depressive Disorder
|
|
Observational
|
|
- Science & Research Islamic Azad University Branch Khozestan
|
Other |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- Depression status(measured by Beck depression inventory (BDII-II))
- Measurements of morning and nocturnal melatonin levels by ELISA kit (cat no. RE54021) from the IBL-Hamburg.
|
92 |
All |
22 Years to 48 Years (Adult) |
NCT01357083 |
9460
CCT-NAPN-21087 |
|
August 2010 |
October 2010 |
October 2010 |
May 20, 2011 |
May 20, 2011 |
|
- Shahnaz Khaleghipour
Isfahan, Iran, Islamic Republic of
|
|
| 91 |
NCT00927173 |
Completed |
Evaluation of the Brainsway Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression Disorder |
- Major Depressive Disorder
|
- Device: Brainsway H-Coil Deep TMS System
- Device: Brainsway H-Coil Deep TMS System (Sham treatment)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- HDRS-21
- Response rate
- Remission rates
- Quality of Life
|
233 |
All |
22 Years to 68 Years (Adult, Older Adult) |
NCT00927173 |
CTP-0001-00
IL-MOH-HTA-4860 |
|
September 2009 |
March 2012 |
June 2012 |
June 24, 2009 |
October 15, 2014 |
|
- University of California (UCLA)
Los Angeles, California, United States - UC Davis Center for Mind & Brain
Sacramento and Davis, California, United States - Smart Brain and Health
Santa Monica, California, United States - (and 19 more...)
|
|
| 92 |
NCT00759395 |
Completed
Has Results |
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD) |
- Anxious Major Depressive Disorder
|
- Drug: AZD2327
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Hamilton Rating Scale for Depression (HAM-D) Total Score.
- Hamilton Rating Scale for Anxiety (HAM-A) Total Score.
- Psychic Anxiety Item of the Hamilton Rating Scale for Depression (HAM-D).
- (and 2 more...)
|
22 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00759395 |
D0880C00021 |
|
January 2009 |
October 2011 |
October 2011 |
September 25, 2008 |
November 8, 2012 |
November 8, 2012 |
- Research Site
Baltimore, Maryland, United States
|
|
| 93 |
NCT03000530 |
Completed |
A Study to Evaluate SAGE-217 in Subjects With Moderate to Severe Major Depressive Disorder |
|
- Drug: SAGE-217
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety and tolerability, as assessed by adverse events [Part A]
- Safety and tolerability, as assessed by clinical laboratory measures [Part A]
- Safety and tolerability, as assessed by vital signs [Part A]
- (and 9 more...)
|
102 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03000530 |
217-MDD-201 |
|
December 2016 |
October 4, 2017 |
October 31, 2017 |
December 22, 2016 |
October 5, 2018 |
|
- Sage Investigational Site
Garden Grove, California, United States - Sage Investigational Site
Orlando, Florida, United States - Sage Investigational Site
Atlanta, Georgia, United States - (and 5 more...)
|
|
| 94 |
NCT01148472 |
Completed |
Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Escitalopram
- Drug: Duloxetine
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- To compare the efficacy of escitalopram with that of duloxetine in outpatients with Major Depressive Disorder (MDD) as assessed by change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at the end of 24 weeks
- To compare the efficacy of escitalopram with that of duloxetine per visit over the 24-week study period in outpatients with MDD.
- To compare the tolerability and safety of escitalopram with that of duloxetine over the 24-week study period in outpatients with MDD.
- To evaluate the discontinuation emergent signs and symptoms during and after taper-down treatment with escitalopram or duloxetine after 24 weeks of treatment assessed by the Discontinuation Emergent Signs and Symptoms Scale (DESS).
|
294 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01148472 |
10990
2004-005069-39 |
|
September 2005 |
September 2006 |
November 2006 |
June 22, 2010 |
November 8, 2016 |
|
|
|
| 95 |
NCT00969150 |
Completed
Has Results |
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Levomilnacipran ER
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
- Change in Sheehan Disability Scale (SDS) Total Score
|
362 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00969150 |
LVM-MD-02 |
|
September 2009 |
November 2010 |
|
September 1, 2009 |
October 25, 2013 |
October 25, 2013 |
- Forest Investigative Site
Scottsdale, Arizona, United States - Forest Investigative Site
Encino, California, United States - Forest Investigative Site
Los Alamitos, California, United States - (and 22 more...)
|
|
| 96 |
NCT00296920 |
Completed |
Deep Brain Stimulation for Refractory Major Depression |
- Major Depressive Disorder
|
- Device: Deep Brain Stimulation
|
Interventional
|
Phase 3 |
- University Health Network, Toronto
- National Alliance for Research on Schizophrenia and Depression
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Rating Scale for Depression, 24-item version (HRSD-24)
- Clinical Global Impression (CGI) of Severity/Improvement
- Psychiatric assessments will be performed every two weeks in the clinic. Once final stimulation parameters are established, psychiatric symptoms will be monitored monthly.
|
10 |
All |
30 Years to 70 Years (Adult, Older Adult) |
NCT00296920 |
02-0118-B |
|
June 2002 |
November 2007 |
|
February 27, 2006 |
February 17, 2009 |
|
- University Health Network
Toronto, Ontario, Canada
|
|
| 97 |
NCT01034462 |
Completed
Has Results |
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Levomilnacipran ER
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
- Change in Sheehan Disability Scale (SDS) Total Score
|
442 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01034462 |
LVM-MD-03 |
|
December 2009 |
December 2011 |
December 2011 |
December 17, 2009 |
October 25, 2013 |
October 25, 2013 |
- Forest Investigative Site 055
Dothan, Alabama, United States - Forest Investigative Site 065
Highlands Ranch, Colorado, United States - Forest Investigative Site 057
Boca Raton, Florida, United States - (and 20 more...)
|
|
| 98 |
NCT00969709 |
Completed
Has Results |
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Levomilnacipran ER
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
- Change in Sheehan Disability Scale (SDS) Total Score
|
724 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00969709 |
LVM-MD-01 |
|
September 2009 |
May 2011 |
|
September 1, 2009 |
October 25, 2013 |
October 25, 2013 |
- Forest Investigative Site
Phoenix, Arizona, United States - Forest Investigative Site
Scottsdale, Arizona, United States - Forest Investigative Site
Beverly Hills, California, United States - (and 35 more...)
|
|
| 99 |
NCT00146523 |
Completed |
An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression |
- Major Depressive Disorder
|
- Drug: Mifepristone
- Drug: placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The change in a measure of psychosis
- The change in a measure of depression
|
247 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00146523 |
C-1073-09 |
|
May 2005 |
July 2006 |
July 2006 |
September 7, 2005 |
February 15, 2012 |
|
- Georgy Koychev M.D.
Sofia, Bulgaria - Luchezar G Hranov M.D.
Sofia, Bulgaria - Svetlozar H Haralanov Ph.D.
Sofia, Bulgaria - (and 16 more...)
|
|
| 100 |
NCT00291239 |
Unknown † |
Effect of Partial Sleep Deprivation on Cognition and Cytokines in Individuals With Major Depression |
|
- Behavioral: partial sleep deprivation
|
Interventional
|
Phase 4 |
- Zentrum für Integrative Psychiatrie
- German Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- cognition
- cytokine concentration
- clinical improvement
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT00291239 |
WADE
DFG-SFB 654, C5 "IL-6-MDE" |
|
February 2006 |
December 2008 |
July 2009 |
February 13, 2006 |
April 3, 2009 |
|
- Zentrum für Integrative Psychiatrie
Kiel, Germany
|
|
Create an RSS feed from your search for:
Download the search results for: